Andrew Rymer is a Partner in Centerview’s healthcare investment banking team. He brings over 20 years of experience, advising companies on a variety of strategic matters.

Mr. Rymer has established himself as one the leading healthcare M&A advisors, having worked on some of the industry’s largest and most important transactions, including:

Large Pharma - Advised Pfizer in multiple transactions including its $68bn acquisition of Wyeth; its $14bn acquisition of Medivation; its $5bn acquisition of Anacor; and its $18bn OTC JV with Glaxo; Merck in its $3bn acquisition of Antelliq; its spinoff of its Organon division; and its worldwide strategic collaboration with Eisai regarding Lenvima; Johnson & Johnson in its $21bn acquisition of Synthes; Novartis in its $1bn sale of its Sandoz US dermatology and generics business to Aurobindo

Biotech – Advised Iveric in its $5.9bn sale to Astellas; Cymabay in its $4.3bn sale to Gilead; Endocyte in its $2.1bn sale to Novartis; Ambrx in its $2bn sale to Johnson & Johnson; CTI Biopharma in its $1.7bn sale to Sobi; Gyroscope Therapeutics in it’s up to $1.5bn sale to Novartis; Micromet in its $1.2 billion sale to Amgen; NeuroDerm in its $1.1bn sale to Mitsubishi Tanabe; Intercept Pharmaceuticals in its $1bn sale to Alfasigma S.p.A.; Nightstar Therapeutics’ in its $877mm sale to Biogen; Curon Biopharmaceutical in its $700mm sale to Merck; ITeos in its development and commercialization collaboration with GSK regarding EOS-448 ($625mm upfront + milestones and royalties); G1 Therapeutics in its $405 sale to Pharmacosmos Group; Celsius Therapeutics in its sale to Abbvie; Arctos Medical in its sale to Novartis; Adverum on its successful 2021 activist defense; LogicBio in its sale to Alexion (largest biotech premium of all time); Chimerix in its sale of TEMBEXA to Emergent BioSolutions

Pharma Services / CMO – Advised Catalent in its $1.2bn acquisition of Paragon Bioservices and $1bn acquisition of Bettera Brands; Kohlberg in its $3bn acquisition of PCI Pharma Services and its acquisitions of Worldwide Clinical Trials and Trinity Life Sciences; inVentiv in its $1.1 billion sale to TH Lee; Standard BioTools in its ~$1bn merger with Somalogic; Nexus Pharmaceuticals in its ~$1bn sale of its Injectable Manufacturing Facility to Eli Lilly; Forge Biologics in its $620mm sale to Ajinomoto; Mayne Pharma in its $475mm sale of Metrics Contract Services to Catalent; Casdin / Viking in their investment in Fluidigm to create Standard BioTools; Phillip-Medisize in its sale to Golden Gate Capital

Healthcare Services – Advised Blackstone, Carlyle and Hellman & Friedman on their $34bn acquisition of Medline Industries; athenahealth in $5.7bn sale to Veritas Capital and Evergreen Coast Capital; US Renal in its sale to Leonard Green

Additionally, Mr. Rymer has executed numerous financing transactions and advisory assignments for a diverse group of industry leaders including Pfizer, Johnson & Johnson, Eli Lilly, Aetna, Wellchoice, Horizon Blue Cross Blue Shield and many of the largest financial sponsors.

Prior to joining Centerview, Mr. Rymer spent 10 years at Goldman Sachs, most recently as a Managing Director with responsibility for the firm’s Healthcare M&A activities. While at Goldman Sachs, he was asked by the firm’s CEO and President to serve as Head of Client Strategy for 18 months in order to help enhance effectiveness across Goldman’s client footprint. Mr. Rymer began his career as an investment banking analyst at Donaldson, Lufkin & Jenrette and worked at Credit Suisse upon its acquisition of DLJ.

Mr. Rymer received a B.A., cum laude and with Honors, from Dartmouth College. Mr. Rymer lives in New York City with his wife and three children.